Chronic Lymphocytic Leukemia
6 competing products in clinical development for Chronic Lymphocytic Leukemia.
Pipeline by Phase
Phase 12
Phase 22
Phase 32
All Products (6)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | Active | 77 |
| Pirtobrutinib + Ibrutinib | Eli Lilly | Phase 3 | Recruiting | 77 |
| Pirtobrutinib | Eli Lilly | Phase 2 | Recruiting | 52 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | Withdrawn | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | Withdrawn | 33 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | Completed | 28 |